

1 **Use of cytokine-induced killer cell therapy in colorectal cancer patients: a systematic**
2 **review and meta-analysis.**

3 **Criteria:** Original Research (Immune Cell therapies and Immune Cell Engineering)

4 **Authors:** Celine Man Ying Li^{1,2*}, Yoko Tomita^{2,3*}, Bimala Dhakal^{1,2}, Runhao Li^{2,3},
5 Jun Li⁴, Paul Drew^{1,2}, Timothy Price^{2,3}, Eric Smith^{1,2,3}, Guy J. Maddern^{1,2} and Kevin
6 Fenix^{1,2}

7 ¹ Department of Surgery, Adelaide Medical School, The University of Adelaide,
8 Adelaide, SA, Australia

9 ² The Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth
10 Hospital, Woodville, SA, Australia

11 ³ Medical Oncology, The Queen Elizabeth Hospital, Woodville, SA, Australia

12 ⁴ Urinary Surgery of Zhumadian Central Hospital, Zhumadian, Henan, China

13 * Authors contributed equally.

14 **Correspondence to:** Dr Kevin Fenix (kevin.fenix@adelaide.edu.au)

15 **Keywords:** colorectal cancer; cytokine-induced killer cell therapy; systematic review

16 **Abstract**

17 **Background:** The number of clinical studies evaluating the benefit of cytokine-
18 induced killer cell (CIK) therapy, an adoptive immunotherapy, for colorectal cancer
19 (CRC) are increasing. In many of these trials CIK therapy was co-administered with
20 conventional cancer therapy. The aim of this review is to systematically assess the
21 available literature, in which the majority were only in Chinese, on CIK therapy for
22 the management of CRC using meta-analysis, and to identify parameters associated
23 with successful CIK therapy implementation.

24 **Methods:** Prospective and retrospective clinical studies which compared CIK
25 therapy to non-CIK therapy in CRC patients were searched for electronically on
26 MEDLINE, Embase, CNKI and Wanfang Data databases. The clinical endpoints of
27 overall survival (OS), progression-free survival (PFS), OS and PFS rates, overall
28 response rate (ORR) and toxicity were meta-analysed using hazard (HR) and
29 relative ratios (RR), and subgroup analyses were performed using Chi-square (Chi²)
30 test and I-square (I²) statistics for study design, disease stage, co-therapy type, and
31 timing of administration.

32 **Results:** In total, 70 studies involving 6,743 patients were analysed. CIK therapy
33 was favoured over non-CIK therapy for OS (HR=0.59, 95% CI: 0.53-0.65), PFS
34 (HR=0.55, 95% CI: 0.47-0.63), and ORR (RR=0.65, 95% CI: 0.57-0.74) without
35 increasing toxicity (HR=0.59, 95% CI 0.16-2.25). Subgroup analyses on OS and PFS
36 by study design (randomised versus non-randomised study design), disease stage
37 (Stage I-III versus Stage IV), co-treatment with dendritic cells (CIK versus DC-CIK
38 therapy), or timing of therapy administration (concurrent versus sequential with co-
39 administered anti-cancer therapy) also showed that the clinical benefit of CIK therapy
40 was robust in any subgroup analysis. Furthermore, co-treatment with dendritic cells
41 did not improve clinical outcomes over CIK therapy alone.

42 **Conclusions:** Compared with standard therapy, patients who received additional
43 CIK cell therapy had favourable outcomes without increased toxicity, warranting
44 further investigation into CIK therapy for the treatment of CRC.

45

46 Abstract Word Count: 299

47 Manuscript Word Count: 4511

48 **Key Message**

49 *What is already known on this topic:*

50 Cytokine-induced killer cell (CIK) therapy is an adoptive immunotherapy used to treat
51 both solid and haematological cancers for over 20 years. It is predominantly used in
52 China, with multiple studies reporting benefit in colorectal cancer (CRC) patients.
53 Despite this, CIK therapy treatment regimens are not widely used, possibly due in
54 part to the majority of the literature about CIK therapy in CRC being reported in
55 Chinese. Further, CIK therapy is commonly combined with other therapies but it is
56 currently not known if there is a specific combination or treatment regimen that is
57 optimal for CRC.

58 *What this study adds:*

59 We report the most comprehensive systematic review to date of CIK therapy for
60 CRC patients, combining both Chinese and English language reports. Patients with
61 CRC who received additional CIK therapy had better survival outcomes than with
62 standard therapy alone. We also showed that the addition of dendritic cells (DC) to
63 CIK therapy, common for CRC treatment, did not provide any clinical benefit over
64 CIK therapy alone, and that CIK therapy is effective whether given concurrently or
65 sequentially to standard treatment regimens.

66 *How this study might affect research, practice, or policy:*

67 Our systematic review of Chinese and English publications shows that CRC patients
68 benefit from the addition of CIK therapy to standard treatment protocols and warrants
69 further international studies.

70 **Introduction**

71 Colorectal cancer (CRC) is the second leading cause of cancer-related death
72 worldwide¹. Patients with locally advanced CRC, including regional lymph node
73 metastases, have a 5-year survival of 75%, which reduces to 15% if there are distant
74 metastases². Survival outcomes for locally advanced and metastatic CRC have
75 steadily improved due to advancements in surgical techniques, peri-operative care
76 and therapeutic options. However, tumour recurrence and therapy resistance remain
77 a challenge, creating the need for new treatment options³.

78 During the last decade immunotherapy has revolutionised cancer treatment, with
79 clinical efficacy established for multiple solid and haematological cancers⁴. Immune
80 checkpoint inhibitors have provided significant clinical benefit, particularly in solid
81 cancers with a high tumour mutation burden⁵. In advanced CRC cases they have
82 become the standard of care for high microsatellite instability (MSI-high)/mismatch
83 repair deficient (dMMR) tumours^{6,7}. Adoptive immunotherapy involves the

84 administration of immune cells expanded and modified in *ex vivo* culture. Most
85 treatments have focused on chimeric antigen receptor T (CAR-T) cell therapy.
86 However, other technologies including dendritic cell (DC) therapy, natural killer (NK)
87 cell therapy, and cytokine-induced killer cell (CIK) therapy are being studied. Unlike
88 immune checkpoint inhibitors, none of the adaptive immunotherapy products are
89 Food and Drug Administration (FDA) approved for CRC treatment⁸.

90 CIK therapy is an autologous, adoptive immunotherapy generated by expanding a
91 heterogeneous population of immune effector cells from peripheral blood
92 mononuclear cells (PBMC)⁹. The cell therapy product contains conventional T cells
93 (CD3+CD56-), natural killer (NK)-like T cells (CD3+CD56+) and NK cells (CD3-
94 CD56+)¹⁰. NK-like T cells are considered the main effector cells in CIK therapy,
95 being able to recognise tumour cells in a major-histocompatibility complex (MHC)-
96 class I unrestricted manner^{11,12}. Hence, guidelines for CIK therapy patient
97 transfusion require that the cell therapy product contain at least 40% NK-like T cells¹³.
98 While CIK therapy is normally combined with conventional chemotherapy, multiple
99 trials which combine CIK therapy with other immunotherapies are being investigated.
100 One of the more popular combinations is combining CIK therapy with autologous DC
101 therapy (DC-CIK therapy) with reports suggesting an improvement in anti-tumour
102 activity¹⁴. China has been a leader in CIK therapy trials for multiple solid tumours,
103 and CIK therapy is commonly provided for CRC treatment in some Chinese
104 hospitals^{15,16}.

105 To date there is a plethora of publications of varying study quality examining the
106 clinical benefit of CIK therapy for CRC. The latest systematic review investigating the
107 clinical efficacy of CIK therapy with chemotherapy in CRC patients was published in
108 2017¹⁶. Since then more studies have been published which support its clinical
109 benefit^{17-19,31}, warranting an updated systematic review to consolidate the evidence
110 for CIK therapy in CRC management. Many of the reports originate in China and are
111 written in Chinese. The objective of this work, therefore, is to systematically assess
112 by meta-analysis the available literature on CIK therapy for the management of CRC,
113 written in either English or Chinese. It includes both prospective and retrospective
114 studies, and also analysed the benefit of parameters commonly modified in trials
115 such as the addition of dendritic cells (DC-CIK therapy) or chemotherapy regimens.

116 **Methods**

117 This systematic review and meta-analysis was performed according to the Preferred
118 Reporting Items for Systematic Reviews and Meta-analysis statement²⁰.

119 *Study selection and search*

120 Studies which compared efficacy of CIK therapy, with or without another anti-cancer
121 treatment, to no treatment or non-CIK anti-cancer treatment in adult patients with
122 CRC diagnosis were identified MEDLINE, Embase, China National Knowledge
123 Infrastructure (CNKI) and Wanfang Data databases. CNKI and Wanfang Data were
124 included as there were multiple studies published in Chinese alone, which were not
125 registered with Embase or MEDLINE. The search strategy for Embase and
126 MEDLINE is described in Supplementary Tables S1 and S2, respectively. For CNKI
127 and Wanfang Data, the following search keywords were used; “cytokine-induced
128 killer cells”, “CIK”, “rectal cancer”, “colorectal cancer”, “colon cancer”, and “clinical

129 trials". No limits were placed on the language in which studies were published and
130 the final search was performed in July 2022. Both prospective and retrospective
131 studies with a parallel-arm design were considered, and the CIK therapy arm
132 included patients who received CIK or DC-CIK (CIK/DC-CIK) therapy. Studies that
133 did not report efficacy endpoints were excluded from this systematic review.

134 *Data extraction and quality assessment*

135 Data collection was performed independently by two authors and discrepancies were
136 resolved by discussion. For studies reported in Chinese, authors who are native in
137 the Chinese language performed the data extraction and translated them into
138 English for collation. The following information was extracted: (1) study
139 characteristics: study design, study site and recruitment period; (2) patient and
140 disease characteristics: number of patients, age, gender, primary tumour location
141 and tumour stage; (3) study intervention: type of CIK therapy and non-CIK anti-
142 cancer therapy received; (4) clinical efficacy endpoints: overall survival (OS),
143 progression-free survival (PFS), 1-, 3- and 5-year OS rates, 1-, 3-, 5-year PFS rates,
144 and overall response rate (ORR); and (6) toxicity.

145 For studies where patients received curative-intent treatment, disease-free survival
146 (DFS) and DFS rates were extracted as PFS and PFS rates. Risk of bias was
147 assessed for the following domains and graded as high, low or unclear: (1) random
148 sequence generation; (2) allocation concealment; (3) blinding of participants and
149 personnel; (4) blinding of outcome assessment; (5) imbalance in baseline
150 characteristics; (6) incomplete outcome data; and (7) uniformity of non-CIK/DC-CIK
151 anti-cancer treatment administered between intervention and control arms.

152 *Data synthesis and analysis*

153 Review Manager 5.4.²¹ was used for pooling data at the study level and statistical
154 analysis. For the multi-intervention-arm study, the control arm was split equally into
155 each intervention arm, so that each pair-wise comparison can be entered separately.
156 Pooled estimates of effect were expressed as a hazard ratio (HR) calculated using
157 an inverse variance model for OS and PFS, and risk ratios (RRs) were calculated
158 using Mantel-Haenszel model for survival rates and ORRs. When individual studies
159 did not describe OS and/or PFS HRs and associated 95% confidence intervals (95%
160 CI), they were estimated from the published Kaplan-Meier curves using a previously
161 described method^{22,23}. The HR and 95% CI were estimated under the assumption for
162 Gaussian distribution for the study that reported median PFS with a p-value²⁴.

163 As heterogeneity due to clinical diversity was expected to be high, a random-effects
164 model was used for all the quantitative analyses performed in this review.
165 Heterogeneity across studies was further assessed by visual inspection and
166 statistically using Chi-square (Chi^2) test and I-square (I^2) statistics for each analysis.
167 A p-value threshold of 0.10 was employed to determine statistical significance for
168 Chi^2 test and I^2 of 30% or less was considered to be a low degree of heterogeneity,
169 30% to 60% to be a moderate degree, and 60% or more to be a high degree.

170 Subgroup analyses were carried out on OS and PFS endpoints to investigate
171 possible sources of heterogeneity. The following subgroup analyses were performed
172 in this review: (1) quality of study design: randomised studies versus non-

173 randomised studies; (2) cancer staging: Stage I-III after resection of primary versus
174 Stage IV (unresectable, metastatic, or recurrent) CRC; (3) CIK therapy type: CIK
175 therapy versus DC-CIK therapy; and (4) CIK therapy administration timing in relation
176 to other anti-cancer therapy: concurrent vs sequential. The subgroup interactions
177 were tested by using the formal statistical test, Chi² test, with significance set at 10%.

178 **Results**

179 *Search results*

180 Through our electronic search 333 records were identified: 129 from Embase, 38
181 from MEDLINE, 60 from CNKI and 106 from Wanfang Data. After removing duplicate
182 publications and studies which titles and/or abstracts indicated were ineligible, 106
183 records were assessed in detail. An additional 36 records were excluded for: only a
184 single study arm; lack of information on clinical efficacy endpoints of interest;
185 overlapping patient cohorts with another publication; being unable to extract data
186 specific to CRC patients; inability to locate original abstracts or full-text articles;
187 patients in all study arms receiving CIK therapy; and patients in the control arm being
188 healthy subjects. Thus, 70 studies containing 16 English^{17,19,25-38} and 44 Chinese<sup>24,39-
189 91</sup> language articles were selected for study synthesis (Figure 1).

190 *Study and patient characteristics*

191 Standardised study cohorts are summarised in Table 1. Two studies^{33,92} were
192 abstracts with the rest being full-text articles. All studies were single-centre studies
193 performed in mainland China. Fifty-four studies<sup>24-26,29,32,35,36,39-42,44-53,55,57-63,65-
194 75,77,78,80-83,85-91</sup> were prospective and 15 studies^{17,19,28,31,33,34,37,38,43,54,56,64,76,79,84} were
195 retrospective in nature. Of the prospective studies, 38<sup>25,26,29,32,35,36,39,40,44-
196 47,49,50,52,53,57,59,61-63,65-69,72-75,80-83,85,87,89,91</sup> were randomised controlled studies.

197 Overall, 6,743 CRC patients, 3,203 in CIK therapy (intervention) arm and 3,540 in
198 non-CIK therapy (control) arm were available for analysis. The median age ranged
199 from 43.2 to 80.0 years old with the youngest being 18 and the oldest being 92 years
200 old. For studies which provided the patient's gender, 3,592 out of 6,017 patients
201 (59.7%) were males. Primary tumour location was reported in thirty studies, with
202 1,657 colon and 1,744 rectum cancer patients. CRC patients diagnosed with all
203 cancer stages were considered for analysis. Three studies evaluated purely Stage III
204 CRC patients^{52,54,65}, while 29 studies evaluated Stage IV CRC
205 patients^{25,27,29,31,36,38,42,46,48,50,53,59,60,62,68-70,75-78,80,84,85,87,89-91}. The remaining studies
206 considered patients with multiple stages. Among patients with known cancer stages,
207 3109 (66.6%) of them had Stage IV disease, comprising the largest group followed
208 by 1,148 patients (24.5%) with Stage III disease, 375 patients with Stage II disease
209 and 46 patients with Stage I disease. Cancer staging for the remaining 1,672
210 patients were either unknown or reported in ranges.

211 *Interventions*

212 In 25 studies^{17,25,27,28,31-37,40,41,46,47,49-51,56,58,65,71,75,77,87}, patients in the intervention arm
213 received CIK therapy, while in 45 studies<sup>19,24,26,29,30,38,39,42-45,48,52-55,57,59-64,66-70,72-
214 74,76,78-86,88-91</sup> DC-CIK therapy was administered. Chemotherapy was the most
215 common co-treatment with CIK or DC-CIK therapy, being utilised in 66 studies<sup>17,19,24-
216 26,28-55,57-80,82-90</sup>. The most commonly utilised chemotherapy regimens were FOLFOX
217 and XELOX, being administered in 43^{17,24,28,29,31,32,34-37,39,41,43,45,48,50,51,55,57-66,69-71,73-}

218 76,78,79,82-85,88,91 and 24^{17,25,26,29,31,34,35,37,40-42,47,58,67,70,72,86,87,89} studies, respectively.
219 Other less commonly used regimens included 5-fluorouracil monotherapy in 6
220 studies^{29,34,37,41,55,79}, capecitabine monotherapy in 7 studies^{17,34,37,55,58,77,84}, FOLFIRI
221 in 8 studies^{19,31,43,48,76,78,83,88} and FOLFOXIRI in 2 studies^{76,88}. In total, 2,847 patients
222 in the intervention arm and 3,033 patients in the control arm were confirmed to have
223 received chemotherapy as a part of study intervention. In 10 studies, local therapy
224 was administered together with CIK/DC-CIK therapy: radiofrequency ablation in 3
225 studies^{27,76,88}, radiotherapy in 6 studies^{19,49,52,56,58,79}, transarterial chemoembolization
226 (TACE) in 1 study⁹⁰ and microwave hyperthermia in one study⁵⁶. In 2 studies, some
227 or all patients in the intervention arm received CIK/DC-CIK therapy alone^{43,81}.

228 *Risk of bias assessment*

229 Risk of bias assessment is shown in Supplementary Figure 1. Among the 38 studies
230 reported to be prospective randomised controlled studies, only 9
231 studies^{26,32,36,45,61,68,72,80,91} described the method of randomisation and no study
232 discussed allocation concealment. None of the included studies provided clarity on
233 blinding of patients, study personnel or investigators. However, it was considered
234 unlikely that a lack of blinding would affect the clinical efficacy endpoints evaluated in
235 the review, namely OS, PFS, OS rate and PFS rate, and ORR. All the studies were
236 thus assessed to be at low risk of performance and detection bias secondary to
237 insufficient blinding. Demographic and clinical characteristics of patients were
238 generally well-balanced across the studies. Four studies^{26,33,51,60} were at unclear risk
239 of selection bias due to a lack of patient characteristics information across treatment
240 arms. Imbalance in age, cancer stage and history of primary cancer resection was
241 noted for 3 studies^{17,37,38} and they were similarly assessed to be at unclear risk of
242 selection bias. Unclear risk of performance bias due to uncertainty around uniformity
243 of non-CIK/DC-CIK treatment across the intervention and control arms was identified
244 in 21 studies^{26,29,31,33,34,38,43,44,48,52,53,55,58,62,76,79-81,83,84,88} with all the studies except
245 one failing to adequately describe study interventions or the proportion of patients
246 receiving various interventions. In the remaining 1 study⁸¹, patients in the
247 intervention arm received DC-CIK therapy alone, while those in the control arm
248 received best supportive care. The risk of attrition bias was rated unclear for 18
249 studies^{17,19,25,27,29,31-33,35-38,40,42,68,79,83,85,90} which did not reveal the number of patients
250 lost in follow-up and for 1 study³⁷ in which 18.8% of patients withdrew from the study
251 prematurely.

252 *Overall survival and progression-free survival*

253 There were 26 studies^{17,19,26,28,31,32,34,37,40,41,43,45,49,50,55,57-59,62,65,69,77,79,81,83,88} involving
254 3,303 patients which contributed data to the meta-analysis on OS (Figure 2A). The
255 pooled HR was 0.59 (95% CI 0.53-0.65) indicating OS benefit of CIK/DC-CIK
256 therapy over the control arm. Heterogeneity among the studies was low ($I^2=11%$,
257 $p=0.30$). For PFS, 20 studies^{19,25-29,31,33-37,58,64,74,76,78,79,84,86} involving 2,593 patients
258 contributed the data to the meta-analysis (Figure 2B). The pooled HR was 0.55
259 (95%CI 0.47-0.63), again favouring CIK/DC-CIK therapy. Heterogeneity among the
260 studies was moderate ($I^2=54%$, $p=0.002$).

261 *Overall survival rates*

262 In total, 27 (2,459 patients)^{17,19,26,28,31,32,34,37,40,41,43,45,49-51,55,57-59,62,65,69,77,79,81,83,88}, 19
263 (2,167 patients)^{17,19,26-28,31,33,34,36,37,40,41,43,50,51,58,69,79,88} and 10 (1,401 patients)
264 ^{17,19,26,28,31,33,34,37,43,58} studies contributed data for 1-year, 3-year and 5-year OS rate
265 meta-analyses respectively (Supplementary Figure 2). The pooled RR for all the
266 analyses favoured CIK/DC-CIK therapy. The 1-year OS rate was 91.7% in the
267 intervention arm and 79.4% in the control arm with a pooled RR of 0.47 (95% CI
268 0.32-0.67). Heterogeneity among the studies was moderate ($I^2=51%$, $p=0.002$). The
269 3-year OS rate was 67.7% in the intervention arm and 51.8% in the control arm with
270 the pooled RR of 0.67 (95% CI 0.59-0.77). There was a moderate level of
271 heterogeneity among the studies ($I^2 = 32%$, $p=0.09$). The 5-year OS rate was 61.2%
272 in the intervention arm and 45.5% in the control arm with RR of 0.69 (95% CI 0.54-
273 0.88). Heterogeneity among the studies was high ($I^2 = 73%$, $P = 0.0001$).

274 *Progression-free survival rates*

275 We identified 10 (1,166 patients)^{17,19,26,28,31,34,37,38,58,79}, 10 (1,156 patients)<sup>17,19,26-
276 28,31,34,36,58,79</sup> and 7 (872 patients) studies^{17,19,26,28,31,34,58} that contributed data for
277 meta-analysis on 1-year, 3-year and 5-year PFS rates respectively (Supplementary
278 Figure 3). All the analyses indicated the superiority of CIK/DC-CIK therapy over non-
279 CIK/DC-CIK therapy. The observed 1-year PFS rate was 86.5% in the intervention
280 arm and 68.1% in the control with the pooled RR of 0.43 (95% CI 0.33-0.55).
281 Heterogeneity among the studies was low ($I^2 = 0%$, $p=0.48$). The 3-year PFS rate
282 was 47.8% in the intervention arm and 30.5% in the control arm. The pooled RR was
283 0.76 (95% CI 0.66-0.87) and heterogeneity among the studies was moderate
284 ($I^2=53%$, $p=0.02$). At 5 years, PFS rate was 46.0% in the intervention arm and 25.9%
285 in the control arm. The pooled RR was 0.71 (95% CI 0.59-0.87) and heterogeneity
286 among the studies was high ($I^2=68%$, $p=0.005$).

287 *Overall response rate*

288 The ORR was 58.7% in the intervention (CIK/DC-CIK) and 39.8% in the control (non
289 CIK/DC-CIK) arm for 3,860 patients from 45 studies<sup>24,25,30,36,39,42,44-49,52-56,61-68,70-78,80-
290 85,87-91</sup> (Figure 3). The pooled RR was 0.65 (95% CI 0.57-0.74) and heterogeneity
291 among the studies was high ($I^2 =85%$, $p<0.00001$).

292 *Toxicity*

293 Toxicity during the study intervention was reported by 31 studies with the majority of
294 the data being provided in a descriptive manner. Two studies^{33,87} compared the rate
295 of any adverse events between the treatment arms and 11
296 studies^{29,36,39,41,42,44,56,61,62,70,72,89} reported adverse events of interest for each arm.
297 Many of the described side effects were thought to be related to chemotherapy
298 administered together with CIK/DC-CIK therapy, including bone marrow suppression,
299 nausea, vomiting, neuropathy, diarrhoea and liver dysfunction. Meta-analysis
300 undertaken indicated equivalent adverse event rate from CIK/DC-CIK and non-
301 CIK/DC-CIK therapy (HR=0.59, 95% CI 0.16-2.25) with the pooled adverse event rate
302 of 53.5% and 68.3%, respectively (Supplementary Figure 4). Heterogeneity was high
303 between the studies ($I^2=80%$, $p=0.02$). Fever was the most frequently reported
304 adverse event associated with CIK/DC-CIK infusion, affecting 6.7% to 29.9% of
305 patients receiving CIK/DC-CIK therapy. Fever, in general, spontaneously resolved or
306 only required symptomatic management.

307 Subgroup analyses

308 Potential sources of heterogeneity were explored by performing subgroup analysis
309 on OS and PFS by study design (randomised versus non-randomised study design),
310 disease stage (Stage I-III versus Stage IV), CIK therapy type (CIK versus DC-CIK
311 therapy), or timing of CIK/DC-CIK therapy administration (concurrent versus
312 sequential with co-administered anti-cancer therapy).

313 Randomised studies versus non-randomised studies

314 Of the 25 studies which provided OS HRs, 8 studies^{29,32,35,36,65,68,69,74} involving 991
315 patients were prospective randomised studies and 17
316 studies^{17,19,26,28,31,33,34,38,43,58,60,64,76,78,79,84,86} involving 2,252 patients were either
317 prospective non-randomised or retrospective studies. An OS benefit of CIK/DC-CIK
318 therapy was demonstrated for both randomised studies (HR=0.57; 95% CI 0.50-0.66)
319 and non-randomised studies (HR=0.59, 95% CI 0.51-0.67) (Figure 4A). A test for
320 subgroup difference did not reach statistical significance ($I^2=0\%$, $p=0.80$). For PFS
321 subgroup analysis, 732 patients from 5 randomised studies^{25,29,35,36,74} and 1,801
322 patients from 14 non-randomised studies^{19,26,28,31,33,34,37,58,64,76,78,79,84,86} were
323 analysed. A benefit from CIK/DC-CIK therapy was again shown for both prospective
324 randomised (HR=0.47, 95% CI 0.31-0.72) and non-randomised studies (HR=0.59,
325 95% CI 0.47-0.63) (Figure 4B). A test for subgroup differences was not statistically
326 significant ($I^2=4.5\%$, $p=0.31$).

327 Stage I-III versus Stage IV

328 Four studies^{32,58,65,79} involving 363 patients with Stage I-III CRC and 12
329 studies^{27,29,31,34,36,38,60,68,69,76,78,84} involving 1,595 Stage IV patients contributed data to
330 the subgroup analysis on OS by the disease stage. HR for Stage I-III patients was
331 0.64 (95% CI 0.48-0.85), while that for Stage IV patients was 0.57 (95% CI 0.50-0.65)
332 and the benefit of CIK/DC-CIK therapy was observed across all stages of CRC
333 (Supplementary Figure 5A). Test for subgroup differences failed to reach statistical
334 significance ($I^2=0\%$, $p=0.48$), although the observed 95% CI was much narrower for
335 Stage IV patients. For the subgroup analysis on PFS, 4 studies^{26,34,58,79} involving 321
336 patients with Stage I-III disease and 8 studies^{25,27,29,31,36,76,78,84} involving 1,045 Stage
337 IV patients were analysed. A benefit from CIK/DC-CIK therapy was demonstrated for
338 both Stage I-III (HR=0.60, 95% CI 0.40-0.88) and Stage IV disease (HR=0.59, 95%
339 CI 0.52-0.67) (Supplementary Figure 5B). A test for subgroup difference was not
340 statistically significant ($I^2=0\%$, $p=0.94$).

341 CIK therapy versus DC-CIK therapy

342 Ten studies^{17,27,28,31-33,35,36,58,65} (1,391 patients) and 16
343 studies^{19,26,29,34,38,43,60,64,68,69,74,76,78,79,84,86} (1,912 patients) which evaluated CIK and
344 DC-CIK therapy respectively were assessed in the subgroup analysis on OS by type
345 of CIK therapy. HR for studies examining CIK therapy was 0.57 (95% CI 0.47-0.69),
346 while that for studies examining DC-CIK therapy was 0.61 (95% CI 0.54-0.69)
347 (Figure 5A). Both types of CIK therapy were found to benefit OS. A test for subgroup
348 differences did not reach statistical significance ($I^2=0\%$, $p=0.58$). Subgroup analysis
349 on PFS by CIK therapy type contained 9 studies^{25,27,28,31,33,35-37,58} involving 1,294
350 patients, where the intervention arm contained CIK therapy, and 11

351 studies^{19,26,29,34,64,74,76,78,79,84,86} involving 1,299 patients, where the intervention arm
352 contained DC-CIK therapy. PFS benefit was demonstrated for both CIK-examining
353 (HR=0.63, 95% CI 0.53-0.74) and DC-CIK-examining studies (HR=0.50, 95% CI
354 0.41-0.61) (Figure 5B). A test for subgroup differences met statistical significance
355 ($I^2=66.5\%$, $p=0.08$) with improved HR seen for DC-CIK, although HRs for the 2
356 subgroups overlapped each other, suggesting that the advantage of DC-CIK over
357 CIK therapy alone may not be clinically meaningful.

358 Concurrent CIK/DC-CIK therapy vs sequential CIK/DC-CIK therapy

359 Subgroup analysis was performed comparing studies where CIK/DC-CIK therapy
360 was administered either concurrently or sequentially with the non-CIK/DC-CIK
361 therapy. For OS analysis, 16 studies^{19,27,31,34,36,38,43,58,60,64,65,69,74,76,84,86} involving
362 2,000 patients with concurrent administration and 8 studies^{17,26,28,29,32,35,68,79} involving
363 846 patients with sequential administration were considered (Figure 6A). CIK/DC-
364 CIK therapy administered in either manner improved OS; the HR was 0.63 (95% CI
365 0.56-0.71) for concurrent administration and 0.59 (95% CI 0.53-0.65) for sequential
366 administration. A test for subgroup differences reached statistical significance
367 ($I^2=76.3\%$, $p=0.04$) with lower HR being observed for sequential administration,
368 although 95% CIs of the 2 subgroups overlapped each other. Subgroup analysis on
369 PFS was similarly in favour of CIK/DC-CIK therapy for both concurrent (HR=0.56,
370 95% CI 0.46-0.67) and sequential administration (HR=0.54, 95% CI 0.46-0.63)
371 (Figure 6B). Twelve studies^{19,25,27,31,34,36,58,64,74,76,84,86} involving 1460 patients who
372 had concurrent administration and 5 studies^{26,28,29,35,79} involving 580 patients who
373 had sequential administration were evaluated and a test for subgroup differences did
374 not meet statistical significance ($I^2=0\%$, $p=0.43$).

375 **Discussion**

376 Chemotherapy with/without biological therapy remains the standard treatment for
377 CRC patients with high-risk resected disease, and the majority of those with
378 advanced disease. This therapeutic approach is associated with limited survival
379 benefit, unlike immunotherapy, which has demonstrated long-term survival outcome
380 in some solid tumours owing to its mechanism of action^{93,94}. New therapeutic
381 approaches which involve modulation of the immune system may provide new
382 treatment options for a broader range of CRC patients, and improve their survival
383 outcome. Autologous adoptive immunotherapy such as CIK therapy represents a
384 highly personalised cancer treatment. While it remains a non-standard treatment
385 option for solid cancers, there are a growing number of clinical trials examining such
386 immunotherapy⁹⁵.

387 Our study demonstrated that providing CIK or DC-CIK therapy to CRC patients
388 improved OS, PFS and ORR compared standard treatment. The upper 95% CI of
389 pooled HRs for 5-year OS rate and 3- and 5-year PFS rates exceeded 0.85, a
390 commonly applied cut-off to delineate no effect from an important effect, raising the
391 possibility that the observed benefit for these endpoints may not be precise.
392 However, for all the other endpoints, the observed HRs favouring CIK/DC-CIK
393 therapy appeared robust. The OS and PFS benefit of CIK/DC-CIK therapy persisted
394 when prospective randomised studies alone were examined in the subgroup analysis,
395 with no subgroup differences being identified compared to non-randomised studies.
396 While the number of randomised studies assessed was small, HRs and associated

397 95% CIs reported by each study, especially for the OS endpoint, were all
398 comparable, indicating consistency in the results and so strengthening the overall
399 finding.

400 Subgroup analysis by CRC disease stage indicated a lack of differences for both OS
401 and PFS. However, the observed 95% CIs associated with the pooled HRs were
402 persistently narrower for Stage IV patients compared to Stage I-III patients, with the
403 upper limits of 95% CIs for Stage I-III patients exceeding 0.85 for both endpoints.
404 Together with the uncertainties around the best way to incorporate CIK/DC-CIK
405 therapy into the established 3-6 months of mono- or doublet- adjuvant chemotherapy,
406 depending on the disease stage and accompanying other prognostic factors, our
407 study highlights that patients with Stage IV disease may be a more suitable target to
408 evaluate CIK/DC-CIK therapy application, at least initially. The immunosuppressive
409 effect of cancer surgery, including T cell and NK cell dysfunction and expansion of
410 myeloid-derived suppressor cells and regulatory T cells in the postoperative period,
411 has been described previously⁹⁶, although how this affects the anti-tumour activity of
412 CIK/DC-CIK therapy is not known.

413 Subgroup analysis based on combining DC therapy with CIK therapy revealed
414 statistically significant subgroup differences in favour of DC-CIK over CIK therapy for
415 PFS, but not for OS. DCs are major antigen-presenting cells and the essential link
416 between the innate and adaptive immune systems⁹⁷. Co-culturing of CIK cells with
417 DCs results in increased CIK cytolytic function, including cytotoxic activity against a
418 tumour cell line resistant to CIK cells cultured in absence of DCs¹⁴. This review
419 observed more patients who received DC-CIK therapy than CIK therapy, however,
420 the results suggest that the addition of DC therapy to CIK therapy does not have a
421 strong clinical benefit, as only statistical significance was observed for PFS and not
422 OS. This result points to the need for future clinical trials investigating the benefit of
423 including DC therapy in CIK therapy, and whether other combinations such as
424 immune checkpoint inhibitors or CAR-T incorporation with CIK therapy may be of
425 better value for CRC patients.

426 Subgroup differences were similarly detected for OS for concurrent versus
427 sequential administration of CIK/DC-CIK. Subgroup analyses for both PFS by CIK
428 therapy type and for OS by CIK therapy administration timing had similar HRs with
429 highly overlapping 95% CIs, making it unclear whether the differences are clinically
430 meaningful. The timing of CIK/DC-CIK delivery for CRC patients may not be critical
431 and could be selected based on logistical issues.

432 There have been two previous publications that systematically reviewed the literature
433 for CIK/DC-CIK therapy in CRC^{16,98}. In 2010, Zhang and Schmidt-Wolf, in
434 cooperation with Stanford University, established the International Registry on CIK
435 Cells (IRCC) to evaluate clinical trials of CIK therapy^{98,99}. The registry identifies both
436 prospective and retrospective clinical trials involving CIK therapy for cancer
437 treatment from PubMed, Web of Science Core Collection, WHO International Clinical
438 Trials Registry Platform, ClinicalTrials.gov as well as proceedings of the American
439 Society of Clinical Oncology and European Cancer Conference Annual Scientific
440 Meetings. In addition, the IRCC incorporates clinical trials submitted by individual
441 researchers for inclusion¹⁰⁰. In 2020 the registry recorded 106 clinical trials, of which
442 only six examined CIK therapy in CRC patients⁹⁸. This contrasts with the twenty-nine
443 trials including 2,610 CRC patients reported in the published systematic review and

444 meta-analysis in 2017 by Zhang *et al.*, which purely compared the clinical benefit of
445 CIK therapy plus chemotherapy to CIK therapy in CRC patients with advanced
446 disease¹⁶. They also utilised two Chinese databases, CNKI and Wanfang Data, in
447 addition to the English databases Cochrane Library, Embase and PubMed. The
448 majority of the studies were published in Chinese similar to our findings.

449 To date China has taken the lead in research of adoptive immunotherapy including
450 CIK therapy^{15,101}. Therefore, the inclusion of articles published in Chinese was
451 necessary to comprehensively review the currently available literature examining
452 clinical efficacy of CIK therapy in CRC. Additionally, the current work included clinical
453 trials which compared CIK therapy to non-CIK treatment not limited to chemotherapy,
454 to increase the number of trials assessed. Consequently, the review considered 70
455 studies involving 6,743 patients and is the largest systemic review on CIK/DC-CIK
456 therapy in CRC. It meta-analysed OS and PFS, the two most important clinical
457 endpoints in assessing efficacy of any cancer therapy. Endpoints covered by
458 Zhang¹⁶ were limited to OS and DFS rates as well as ORR. The CRC population
459 covered by this review is also broader having included patients at all stages.

460 This study has a number of limitations. The heterogeneity observed in the clinical
461 study design requires caution when interpreting results. There are general guidelines
462 for the production of the CIK therapy. The CIK therapy product is generated from
463 PBMCs cultured for 21-28 days in the presence of anti-CD3 stimulation and the
464 cytokines interferon-gamma and interleukin-2. Prior to transfusion, the therapy
465 product is expected to have minimum percentage of NK-like T cells¹⁰². While having
466 basic production guidelines makes reproducing this therapy achievable, we observed
467 heterogeneity in the culture systems used to generate these cells, including the
468 media, concentration of stimuli and cytokines used, and intervals of cytokine addition
469 in culture. Characterisation of the cell therapy product prior to transfusion to meet the
470 guidelines was normally not provided. Clinical parameters such as anti-cancer
471 treatment history, demographics, and number of treatment cycles were also
472 observed to be heterogenous among the studies analysed. These variables could
473 contribute to the heterogeneity observed in our analysis that was not rectified by our
474 subgroup analyses. As the studies identified were all undertaken in China, clinical
475 trials in non-Chinese ethnicity are needed to confirm its efficacy outside of Chinese
476 patients. Finally, the possibility of publication bias was raised as only a handful of
477 studies reported negative outcomes of CIK/DC-CIK therapy for the efficacy
478 endpoints assessed.

479 Despite these limitations, our data strongly support that complementing conventional
480 treatment regimens with CIK/DC-CIK therapy in patients with CRC provides clinical
481 benefits. By highlighting the parameters that contribute to the heterogeneity in the
482 study designs, we suggest that standardisation of these will lead to greater adoption
483 of CIK therapy worldwide.

484 **Conclusion**

485 CIK therapy in combination with standard treatments, in particular chemotherapy,
486 provides clinical benefit for CRC patients. The benefit existed whether the included
487 studies were prospective and randomised or not, strengthening the finding. CIK
488 therapy was well tolerated, with fever being the most common adverse event. While
489 DC therapy is commonly combined with CIK therapy for CRC patients, our study

490 suggests that this may not provide extra benefit. The findings support further
491 evaluation of the clinical utility of CIK therapy in CRC.

492

493

494 **Declarations**

495 **Contributors:** Conception Design: CMYL, YT and KF. Collection and/or assembly of
496 data: CMYL, YT, RL, and JL. Data analysis and interpretation: CMYL, YT, BD, ES
497 and KF. Manuscript Writing: CMYL, YT, ES, PD, and KF. Final Approval of
498 Manuscript: CMYL, YT, BD, RL, JL, PD, ES, TP, GM, and KF.

499 **Funding:** This work was supported by The Hospital Research Foundation
500 (THRF)/Cancer Council SA Beat Cancer Hospital Research Package (GM) and a
501 Tour de Cure Early Career Grant (KF). BD was supported by a Schlumberger
502 Foundation Faculty For Future Fellowship and KF was supported by a THRF Early
503 Career Fellowship.

504 **Competing Interests:** The authors have no relevant financial or non-financial
505 interests to disclose.

506 **Data Availability:** All data generated or analysed during this study are included in
507 this published article and its supplementary material. The datasets used and/or
508 analysed during the current study are available from the corresponding author on
509 reasonable request.

510

511 **Reference**

- 512 1 International Agency for Research on Cancer. *The Global Cancer Observatory 2020;*
513 *Colorectal Cancer*, <[https://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-](https://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact-sheet.pdf)
514 [fact-sheet.pdf](https://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact-sheet.pdf)> (2020).
- 515 2 National Cancer Institute. *SEER Cancer Stat Facts: Colorectal Cancer*,
516 <<https://seer.cancer.gov/statfacts/html/colorect.html>> (2022).
- 517 3 Sievers, C. K. *et al.* The Multidisciplinary Management of Colorectal Cancer: Present and
518 Future Paradigms. *Clin Colon Rectal Surg* **29**, 232-238, doi:10.1055/s-0036-1584292 (2016).
- 519 4 Kruger, S. *et al.* Advances in cancer immunotherapy 2019 - latest trends. *J Exp Clin Cancer*
520 *Res* **38**, 268, doi:10.1186/s13046-019-1266-0 (2019).
- 521 5 Chan, T. A. *et al.* Development of tumor mutation burden as an immunotherapy biomarker:
522 utility for the oncology clinic. *Annals of oncology : official journal of the European Society for*
523 *Medical Oncology* **30**, 44-56, doi:10.1093/annonc/mdy495 (2019).
- 524 6 Andre, T. *et al.* Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
525 *N Engl J Med* **383**, 2207-2218, doi:10.1056/NEJMoa2017699 (2020).
- 526 7 Lenz, H. J. *et al.* First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-
527 High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142
528 Study. *Journal of clinical oncology : official journal of the American Society of Clinical*
529 *Oncology* **40**, 161-170, doi:10.1200/JCO.21.01015 (2022).
- 530 8 Fan, A. *et al.* Immunotherapy in colorectal cancer: current achievements and future
531 perspective. *Int J Biol Sci* **17**, 3837-3849, doi:10.7150/ijbs.64077 (2021).
- 532 9 Schmidt-Wolf, I. G., Negrin, R. S., Kiem, H. P., Blume, K. G. & Weissman, I. L. Use of a SCID
533 mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent
534 antitumor cell activity. *The Journal of experimental medicine* **174**, 139-149,
535 doi:10.1084/jem.174.1.139 (1991).

- 536 10 Gao, X. *et al.* Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer
537 Immunotherapy. *Front Immunol* **8**, 774, doi:10.3389/fimmu.2017.00774 (2017).
- 538 11 Pievani, A. *et al.* Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that
539 acquires NK function and retains TCR-mediated specific cytotoxicity. *Blood* **118**, 3301-3310,
540 doi:10.1182/blood-2011-02-336321 (2011).
- 541 12 Zhang, Q. *et al.* Phenotypic and functional characterization of cytokine-induced killer cells
542 derived from preterm and term infant cord blood. *Oncology reports* **32**, 2244-2252,
543 doi:10.3892/or.2014.3457 (2014).
- 544 13 Linn, Y. C., Lau, L. C. & Hui, K. M. Generation of cytokine-induced killer cells from leukaemic
545 samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. *British*
546 *journal of haematology* **116**, 78-86, doi:10.1046/j.1365-2141.2002.03247.x (2002).
- 547 14 Marten, A. *et al.* Interactions between dendritic cells and cytokine-induced killer cells lead to
548 an activation of both populations. *Journal of immunotherapy (Hagerstown, Md. : 1997)* **24**,
549 502-510, doi:10.1097/00002371-200111000-00007 (2001).
- 550 15 Li, X. D. *et al.* Review of Chinese clinical trials on CIK cell treatment for malignancies. *Clinical*
551 *& translational oncology : official publication of the Federation of Spanish Oncology Societies*
552 *and of the National Cancer Institute of Mexico* **14**, 102-108, doi:10.1007/s12094-012-0768-4
553 (2012).
- 554 16 Zhang, L. *et al.* Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells
555 immunotherapy combined with chemotherapy for treatment of colorectal cancer in China: a
556 meta-analysis of 29 trials involving 2,610 patients. *Oncotarget* **8**, 45164-45177,
557 doi:10.18632/oncotarget.16665 (2017).
- 558 17 Pan, Q. Z. *et al.* Efficacy of adjuvant cytokine-induced killer cell immunotherapy in patients
559 with colorectal cancer after radical resection. *Oncoimmunology* **9**, 1752563,
560 doi:10.1080/2162402X.2020.1752563 (2020).
- 561 18 Wang, C. *et al.* 101P - Combined cellular immunotherapy and chemotherapy improves
562 clinical outcome and displays safety in the treatment of patients with colorectal cancer.
563 *Annals of Oncology* **30**, ix36, doi:<https://doi.org/10.1093/annonc/mdz421.023> (2019).
- 564 19 Xie, Y. *et al.* Effect of dendritic cell-cytokine-induced killer cells in patients with advanced
565 colorectal cancer combined with first-line treatment. *World J Surg Oncol* **15**, 209,
566 doi:10.1186/s12957-017-1278-1 (2017).
- 567 20 Page, M. J. *et al.* The PRISMA 2020 statement: an updated guideline for reporting systematic
568 reviews. *BMJ* **372**, n71, doi:10.1136/bmj.n71 (2021).
- 569 21 Review Manager (RevMan) v. 5.4.1 (2020).
- 570 22 Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S. & Sydes, M. R. Practical methods for
571 incorporating summary time-to-event data into meta-analysis. *Trials* **8**, 16,
572 doi:10.1186/1745-6215-8-16 (2007).
- 573 23 Altman, DG & JM, B. How to obtain the confidence interval from a P value. *BMJ*,
574 doi:10.1136/bmj.d2090 (2011).
- 575 24 Zhang, L., Li, X., Huang, K., Hu, Z. & Tan, X. Long-term effect of DC-CIK cells immunology
576 therapy in patients with advanced colorectal cancer (Chinese Article). *Progress in Modern*
577 *Biomedicine* **16**, 4348-4351, doi:10.13241/j.cnki.pmb.2016.22.039 (2016).
- 578 25 Du, C. *et al.* Autologous cytokine-induced killer cells combined with chemotherapy in the
579 treatment of advanced colorectal cancer: a randomized control study. *The Chinese-German*
580 *Journal of Clinical Oncology* **12**, 487-491, doi:10.1007/s10330-013-1214-y (2013).
- 581 26 Gao, D. *et al.* Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-
582 induced killer cells improves survival in gastric and colorectal cancer patients. *PLoS One* **9**,
583 e93886, doi:10.1371/journal.pone.0093886 (2014).
- 584 27 Li, X. *et al.* Phase II/III Study of Radiofrequency Ablation Combined with Cytokine-Induced
585 Killer Cells Treating Colorectal Liver Metastases. *Cellular physiology and biochemistry* :

586 *international journal of experimental cellular physiology, biochemistry, and pharmacology* **40**,
587 137-145, doi:10.1159/000452531 (2016).

588 28 Li, X. *et al.* Retrospective analysis of the efficacy of adjuvant cytokine-induced killer cell
589 immunotherapy combined with chemotherapy in colorectal cancer patients after surgery.
590 *Clinical & translational immunology* **11**, e1368, doi:10.1002/cti2.1368 (2022).

591 29 Lin, T., Song, C., Chuo, D. Y., Zhang, H. & Zhao, J. Clinical effects of autologous dendritic cells
592 combined with cytokine-induced killer cells followed by chemotherapy in treating patients
593 with advanced colorectal cancer: a prospective study. *Tumour biology : the journal of the*
594 *International Society for Oncodevelopmental Biology and Medicine* **37**, 4367-4372,
595 doi:10.1007/s13277-015-3957-2 (2016).

596 30 Liu, B., Zhong, C. & Wu, B. THERAPEUTIC EFFECTS OF COMBINATION OF CHEMOTHERAPY
597 AND BIOTHERAPY ON COLORECTAL CANCER AND ITS EFFECTS ON IMMUNE CELLS, NK, IFN- γ
598 AND IL-2. *Acta Medica Mediterranea* **2**, 105, doi:10.19193/0393-6384_2019_2_158 (2019).

599 31 Pan, Q. Z. *et al.* Retrospective analysis of the efficacy of cytokine-induced killer cell
600 immunotherapy combined with first-line chemotherapy in patients with metastatic
601 colorectal cancer. *Clinical & translational immunology* **9**, e1113, doi:10.1002/cti2.1113
602 (2020a).

603 32 Peng, H. *et al.* Effects of Autologous Cytokine-Induced Killer Cells Infusion in Colorectal
604 Cancer Patients: A Prospective Study. *Cancer biotherapy & radiopharmaceuticals* **32**, 221-
605 226, doi:10.1089/cbr.2017.2246 (2017).

606 33 Wang, C. *et al.* 101P - Combined cellular immunotherapy and chemotherapy improves
607 clinical outcome and displays safety in the treatment of patients with colorectal cancer.,
608 *Annals of Oncology*, **30** (2019).

609 34 Xu, H. *et al.* Analysis of the Clinical Efficacy of Dendritic Cell -cytokine Induced Killer Cell-
610 based Adoptive Immunotherapy for Colorectal Cancer. *Immunol Invest* **50**, 622-633,
611 doi:10.1080/08820139.2020.1781881 (2021).

612 35 Zhang, J. *et al.* Effects of cytokine-induced killer cell treatment in colorectal cancer patients:
613 a retrospective study. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*
614 **68**, 715-720, doi:10.1016/j.biopha.2014.07.010 (2014).

615 36 Zhao, H. *et al.* Autologous Cytokine-Induced Killer Cells Improves Overall Survival of
616 Metastatic Colorectal Cancer Patients: Results From a Phase II Clinical Trial. *Clinical*
617 *colorectal cancer* **15**, 228-235, doi:10.1016/j.clcc.2016.02.005 (2016).

618 37 Zhu, Y. *et al.* Efficacy of postoperative adjuvant transfusion of cytokine-induced killer cells
619 combined with chemotherapy in patients with colorectal cancer. *Cancer Immunol*
620 *Immunother* **62**, 1629-1635, doi:10.1007/s00262-013-1465-z (2013).

621 38 Zhu, H. *et al.* Immune response, safety, and survival and quality of life outcomes for
622 advanced colorectal cancer patients treated with dendritic cell vaccine and cytokine-induced
623 killer cell therapy. *BioMed research international* **2014**, 603871, doi:10.1155/2014/603871
624 (2014).

625 39 Bian, J. Study on chemotherapy combined with DC-CIK on colorectal cancer (Chinese Article).
626 *Chin J Surg Onco* **5**, 306-309, doi:10.3969/j.issn.1674-4136.2013.05.011 (2013).

627 40 Cai, X., Xiong, W., Li, Y. & Shen, T. Clinical Research of the Treatment on patients of Mid-low
628 locally rectal cancer after operation with cytokine induced killer cells (Chinese Article). *The*
629 *Practical Journal of Cancer* **25**, 37-39, doi:10.3969/j.issn.1001-5930.2010.01.011 (2010).

630 41 Cai, W. & Li, W. Clinical study of autologous CIK cells combined with synchronous
631 radiotherapy and chemotherapy in the treatment of elderly rectal cancer patients (Chinese
632 Article). *Modern Preventive Medicine* **40**, 1564-1567 (2013).

633 42 Cai, P. Clinical observation of DC-CIK combined with chemotherapy on advanced colon
634 cancer (Chinese Article). *World Latest Medicine Information* **17**, 155-156,
635 doi:10.19613/j.cnki.1671-3141.2017.71.132 (2017).

- 636 43 Chao, Y., Yang, X., Zhou, F., Zhang, Q. & Qian, Q. The relationship between DC-CIK and
637 colorectal cancer prognoses and its influencing factors (Chinese Article). *Journal of*
638 *Pharmaceutical Practice* **34**, 366-371, doi:10.3969/j.issn.1006-0111.2016.04.022 (2016).
- 639 44 Chen, F. *et al.* Dendritic cell - cytokine induced killer cells combined with chemotherapy and
640 targeted therapy in treatment of advanced colon cancer patients (Chinese Article). *Modern*
641 *Oncology* **23**, 1686-1690, doi:10.3969/j.issn.1672-4992.2015.12.17 (2014).
- 642 45 Chen, Y. Clinical study of DC-CIK combined with chemotherapy in the treatment of colon
643 cancer (Chinese Article). *Health For Everyone* **14** (2014).
- 644 46 Chu, F., Liang, Q., Wang, L., Du, X. & Jiang, Y. Effect of mFOLFOX6 chemotherapy combined
645 with autologous CIK cells on T lymphocyte subsets in patients with advanced colorectal
646 cancer (Chinese Article). *World Chinese Digestive Journal* **24**, 2279-2285,
647 doi:10.11569/wcjd.v24.i14.2279 (2016).
- 648 47 Deng, Z., Liao, Q. & Liu, J. Evaluation of the efficacy of CIK cell sequential systemic
649 chemotherapy in advanced colorectal cancer (Chinese Article). *China Health Nutrition* **28**, 62,
650 doi:10.3969/j.issn.1004-7484.2018.03.074 (2018).
- 651 48 Dong, M. Efficacy of DC-CIK adoptive immunotherapy in combination with chemotherapy in
652 the treatment of metastatic colorectal cancer (Chinese Article). *Dietary Health Care* **5**, 49,
653 doi:10.3969/j.issn.2095-8439.2018.50.062 (2018).
- 654 49 Fan, M., Ye, W., Yao, J. & Li, X. Clinical analysis of cytokine induced killer cells combined with
655 concurrent chemoradiotherapy in the treatment of local recurrence of rectal neoplasms
656 (Chinese Article). *Chin J Postgrad Med* **36**, 21-25, doi:10.3760/cma.j.issn.1673-
657 4904.2013.02.008 (2013).
- 658 50 Fang, L. Observation of the efficacy of CIK cell immunotherapy on postoperative rectal
659 cancer (Chinese Article). *The World Clinical Medicine* **10**, 41,44 (2016).
- 660 51 Feng, Y., Zhu, Z., Sun, B. & Wang, B. Efficacy evaluation of CIK cell immunotherapy for
661 postoperative rectal cancer (Chinese Article). *Clinical Research*, 366-367 (2014).
- 662 52 Feng, F. & Wang, W. Clinical observation of chemotherapy combined with DC-CIK cell
663 immunotherapy for stage III colorectal cancer (Chinese Article). *Modern diagnosis and*
664 *treatment* **28**, 3832-3833, doi:10.3969/j.issn.1001-8174.2017.20.065 (2017).
- 665 53 Guo, J. & Ma, L. Efficacy of dendritic cell-cytokine-induced killer cell biology combined with
666 portal vein embolization on liver metastasis of colorectal cancer (Chinese Article). *Sanxi Med*
667 *J* **48**, 936-938, doi:10.3969/j.issn.0253-9926.2019.08.022 (2019).
- 668 54 He, J. & Zhang, C. Analysis of the effect of postoperative chemotherapy combined with DC-
669 CIK cell therapy for colorectal cancer (Chinese Article). *J Med Theor & Prac* **31**, 2545-
670 2546,2552, doi:10.19381/j.issn.1001-7585.2018.17.004 (2018).
- 671 55 Jiang, Y. Efficacy of DC-CIK cells in the treatment of advanced colorectal cancer (Chinese
672 Article). *Frontiers of medicine* **6**, 230-231 (2016).
- 673 56 Leng, N., Nie, W., Zhao, Y. & Hu, Z. The effect of mCIK combined with IMRT and microwave
674 hyperthermia in the treatment of locally advanced rectal cancer (Chinese Article). *Oncology*
675 *Progress* **14**, 861-863,867, doi:10.11877/j.issn.1672-1535.2016.14.09.11 (2016).
- 676 57 Li, S., Li, Y., Liang, J. & Liu, X. The study of clinical application of DC-CIK combined with
677 chemotherapy on colon cancer (Chinese Article). *Chinese Journal of Immunology* **28**, 835-839,
678 doi:10.3969/j.issn.1000-484X.2012.09.016 (2012).
- 679 58 Li, Y., Jin, A., Chen, S., Song, C. & Zhang, G. Efficacy of Adjuvant Chemotherapy Combined
680 with CIK Cell Immunotherapy in 130 Patients with Postoperative Colorectal Cancer (Chinese
681 Article). *Journal of Chinese Oncology* **21**, 843-847, doi:10.11735/j.issn.1671-
682 170X.2015.10.B013 (2015).
- 683 59 Liu, W. Clinical effect of the application of DC-CIK combined with chemotherapy in the
684 treatment of colon cancer (Chinese Article). *China Continuing Medical Education* **6**, 43-44,
685 doi:10.3969/J.ISSN.1674-9308.2014.08.024 (2014).

686 60 Liu, G., Li, Y., Chen, Z. & Chen, L. Clinical efficacy of DC-CIK cells combined with systemic
687 intravenous chemotherapy in the treatment of advanced colorectal cancer with diffuse liver
688 metastasis (Chinese Article). *Journal of Chongqing Medical University* **39**, 368-373,
689 doi:10.13406/j.cnki.cyx.000060 (2014).

690 61 Liu, C. Effect of DC-CIK combined with FOLFOX6 chemotherapy regimen in the treatment of
691 elderly colorectal cancer patients (Chinese Article). *Medical Journal of Chinese People's
692 Health* **32**, 55-57, doi:10.3969/j.issn.1672-0369.2020.13.021 (2020).

693 62 Liu, Y., Ge, S. & Liu, Q. Efficacy of Transcatheter Arterial Chemoembolization combined with
694 DC-CIK for colorectal cancer patients with liver metastasis (Chinese Article). *The Practical
695 Journal of Cancer* **31**, 1277-1279, doi:10.3969/j.issn.1001-5930.2016.08.018 (2016).

696 63 Liu, R. & Shi, N. Efficacy of dendritic cells and cytokine induced killer cells combination
697 chemotherapy for colon cancer and influences on immune function changes (Chinese
698 Article). *Chin J Clin Oncol Rehabil* **23**, 401-404, doi:10.13455/j.cnki.cjcor.2016.04.05 (2016).

699 64 Liu, D. *et al.* Clinical efficacy of postoperative chemotherapy in combination with CIK
700 immunotherapy in rectal cancer patients (Chinese Article). *Chinese Journal of General
701 Surgery* **25**, 1186-1192, doi:10.3978/j.issn.1005-6947.2016.08.017 (2016).

702 65 Lv, Y., Shi, Y., Wang, Z., Mao, H. & Dai, G. A randomised study of cytokine-induced killer cells
703 combined with chemotherapy for advanced colorectal cancer. *Oncology Progress*, 505-510,
704 doi:10.11877/j.issn.1672-1535.2014.12.05.20 (2014).

705 66 Ma, J. DC-CIK Combined with Chemotherapy for Colonic Cancer:An Analysis on the Effect of
706 25 Cases. *Clin J Coloproctol* **39**, 8-9 (2019).

707 67 Niu, S. DC-CIK combined with chemotherapy plus targeted therapy is used for advanced
708 colon cancer (Chinese Article). *Journal of Basic and Clinical Oncology* **29**, 355-356,357,
709 doi:10.3969/j.issn.1673-5412.2016.04.026 (2016).

710 68 Pu, L., Jin, L., Li, T., Hu, W. & Liang, X. The effect of DC-CIK combined with chemotherapy on
711 patients with liver metastases after radical resection of colorectal cancer and its influence on
712 the expression of TRF1 and TRF2 (Chinese Article). *Chin J Diffc and Compl Cas* **20**, 446-
713 449,455, doi:10.3969/j.issn.1671-6450.2021.05.003 (2021).

714 69 Rui, T. *et al.* Activated DC combined with CIK immunotherapy for patients with advanced
715 colorectal cancer (Chinese Article). *Zhejiang Medicine* **37**, 1505-1509 (2012).

716 70 Sun, J. The effect of DC-CIK combined with chemotherapy plus targeted therapy was
717 observed in patients with advanced colon cancer (Chinese Article). *Dietary Health Care* **46**,
718 36 (2020).

719 71 Wang, R. *et al.* Effects of IL-2- and IL-15-induced CIK Cells Combined with Chemotherapy
720 Treatment for Colorectal Cancer (Chinese Article). *Journal of Junming Medical University* **35**,
721 97-101, doi:10.3969/j.issn.1003-4706.2014.11.025 (2014).

722 72 Wang, L., Zhao, D., Cao, Y. & Li, R. The application of DC-CIK biological immunotherapy
723 combined with chemotherapy and targeted therapy in advanced colon cancer (Chinese
724 Article). *International Herald of Medicine and Health (IMHGN)* **22**, 42-44,
725 doi:10.3760/cma.j.issn.1007-1245.2016.01.012 (2016).

726 73 Wang, X., Zhang, J., Hui, L. & Luo, Y. Effect of chemotherapy combined with DC-CIK cell
727 immunotherapy on advanced colorectal cancer and immune function (Chinese Article). *Med
728 J NDFNC* **38**, 351-356, doi:10.16021/j.cnki.1007-8622.2017.06.001 (2017).

729 74 Weng, H., Shen, D., Mao, W. & Han, L. Clinical efficacy of DC-CIK immunotherapy combined
730 with chemotherapy in treatment of advanced colorectal cancer (Chinese Article). *Zhejiang
731 Medicine* **37**, 625-629 (2013).

732 75 Weng, J. *et al.* Clinical observation of co-treatment with CIK cells and dendritic cells for
733 advanced rectal cancer (Chinese Article). *Chin J Clin Oncol Rehabil* **21**, 1040-1043,
734 doi:10.13455/j.cnki.cjcor.2014.09.06 (2014).

- 735 76 Wu, Y. *et al.* Influence of DC-CIK on circulating tumour cells in patients with liver metastasis
736 after radical resection of colorectal cancer and its therapeutic efficacy (Chinese Article). *Chin*
737 *J Cancer Biother* **25**, 89-93, doi:10.3872/j.issn.1007-385x.2018.01.016 (2018).
- 738 77 Yan, H., Wu, J., Sun, W. & Wang, W. Clinical Observation of Elderly Patients with Advanced
739 Colorectal Cancer Treated with CIK Cells Combined with Chemotherapy (Chinese Article).
740 *Journal of Basic and Clinical Oncology* **27**, 286-288, doi:10.3969/j.issn.1673-
741 5412.2014.04.005 (2014).
- 742 78 Yin, L. *et al.* Efficacy of dendritic cells/cytokine induced killer cells adoptive immunotherapy
743 combined with chemotherapy in treatment of metastatic colorectal cancer (Chinese Article).
744 *Clin J Cancer Biother* **20**, 217-224 (2013).
- 745 79 Ying, M., Wei, Z., Yang, J., Chen, L. & Zheng, Q. Retrospective analysis of Pos-operative
746 chemo-radiotherapy combined with DC-CIK in the treatment of patients with colorectal
747 cancer (Chinese Article). *The Practical Journal of Cancer* **25**, 274-276,282,
748 doi:10.3969/j.issn.1001-5930.2010.03.016 (2010).
- 749 80 Yuan, J., Peng, D., Li, J. & Wang, M. Clinical research of dendritic cells combined with
750 cytokine induced killer cells therapy for advanced colorectal cancer (Chinese Article). *Chinese*
751 *General Practice* **14**, 4139-4141, doi:10.3969/j.issn.1007-9572.2011.36.007 (2016).
- 752 81 Yue, L. *et al.* Clinical research of adoptive immunotherapy with killer cells induced by
753 autologous dendritic cells vaccine in palliative care of elder patients with colorectal
754 carcinoma (Chinese Article). *Sichuan Medical Journal* **37**, 1228-1232,
755 doi:10.16252/j.cnki.issn1004-0501-2016.11.010 (2016).
- 756 82 Zang, Y., Ding, L. & Jiang, Z. Clinical efficacy of DC - CIK combined with FOLFOX6
757 chemotherapy in treatment of elderly patients with colorectal cancer and its effect on serum
758 hCAP18 and APE1 autoantibodies (Chinese Article). *Journal of Practical Oncology* **34**, 449-
759 453 (2019).
- 760 83 Zhang, J., Geng, J., Han, Z. & Gao, X. Observation of clinical efficacy of chemotherapy
761 combined with CIK/DC cell therapy for advanced colon cancer (Chinese Article). *ACTA*
762 *Academia Medicine XUZHOU* **31**, 457-459, doi:10.3969/j.issn.1000-2065.2011.07.008 (2011).
- 763 84 Zhang, J., Ye, Z., Huang, L., Huang, T. & Zhang, Z. Clinical discussion of DC-CIK cell
764 combination chemotherapy in the treatment of advanced colorectal cancer (Chinese Article).
765 *Zhejiang Clinical Medicine* **17**, 2105-2106,2109 (2015).
- 766 85 Zhang, W. Clinical observation of DC-CIK adoptive immunotherapy combined with
767 chemotherapy in the treatment of advanced colorectal cancer (Chinese Article). *Practical*
768 *integrative medicine clinical* **17**, 47-48, doi:10.13638/j.issn.1671-4040.2017.04.027 (2017).
- 769 86 Zhang, Z. *et al.* Clinical efficacy of dendritic cells/cytokine induced killer cells immunotherapy
770 combined with chemotherapy for advanced colorectal cancer (Chinese Article). *Med J West*
771 *China* **34**, 415-419, doi:10.3969/j.issn.1672-3511.2022.03.019 (2022).
- 772 87 Zhao, B. *et al.* Clinical efficacy of DC-CIK combined with chemotherapy and targeted therapy
773 for advanced colon cancer (Chinese Article). *Heilongjiang Medicine and Pharmacy* **41**, 5-6,
774 doi:10.3969/j.issn.1008-0104.2018.05.003 (2018).
- 775 88 Zhao, H., Yun, S., Li, C., Su, W. & Zhang, X. Efficacy of DC-CIK combined with chemotherapy
776 and radiofrequency ablation in the treatment of postoperative liver metastasis of colorectal
777 cancer (Chinese Article). *Modern Instruments and Medical* **25**, 57-61,
778 doi:10.11876/mimt201902015 (2019).
- 779 89 Zhao, W. *et al.* To Explore the Effect of DC-CIK Combine with Chemotherapy plus Targeted
780 Therapy for Advanced Colorectal Cancer (Chinese Article). *China Continuing Medical*
781 *Education* **7**, 93-95, doi:10.3969/j.issn.1674-9308.2015.26.066 (2015).
- 782 90 Zhou, D., Cao, S., Li, Q., Long, W. & Li, Y. Clinical Study of TACE Combined with DC-CIK
783 Biotherapy on the Treatment of Patients with Clorectal Liver Metastases. *Journal of Clinical*
784 *Radiology* **35**, 771-774 (2016).

785 91 Zhou, Q. Observation effect of biological immune method in the treatment of patients with
786 advanced colorectal cancer (Chinese Article). *Contemporary Chinese Medicine* **22**, 37-39
787 (2015).

788 92 Guo, R., Piao, H., Shi, G., Zhang, G. & Zhang, R. Analysis of the efficacy of CIK therapy in
789 adjuvant treatment of colorectal cancer. **38**, e15022-e15022,
790 doi:10.1200/JCO.2020.38.15_suppl.e15022 (2020).

791 93 Larkin, J. *et al.* Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced
792 Melanoma. *N Engl J Med* **381**, 1535-1546, doi:10.1056/NEJMoa1910836 (2019).

793 94 Reck, M. *et al.* Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for
794 Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \geq 50. *J Clin*
795 *Oncol* **39**, 2339-2349, doi:10.1200/JCO.21.00174 (2021).

796 95 Xin Yu, J., Hubbard-Lucey, V. M. & Tang, J. The global pipeline of cell therapies for cancer.
797 *Nat Rev Drug Discov* **18**, 821-822, doi:10.1038/d41573-019-00090-z (2019).

798 96 Bakos, O., Lawson, C., Rouleau, S. & Tai, L. H. Combining surgery and immunotherapy:
799 turning an immunosuppressive effect into a therapeutic opportunity. *J Immunother Cancer* **6**,
800 86, doi:10.1186/s40425-018-0398-7 (2018).

801 97 Patente, T. A. *et al.* Human Dendritic Cells: Their Heterogeneity and Clinical Application
802 Potential in Cancer Immunotherapy. *Frontiers in immunology* **9**, 3176,
803 doi:10.3389/fimmu.2018.03176 (2018).

804 98 Zhang, Y. & Schmidt-Wolf, I. G. H. Ten-year update of the international registry on cytokine-
805 induced killer cells in cancer immunotherapy. *J Cell Physiol* **235**, 9291-9303,
806 doi:10.1002/jcp.29827 (2020).

807 99 Wolf, B. *et al.* Safety and Tolerability of Adoptive Cell Therapy in Cancer. *Drug Saf* **42**, 315-
808 334, doi:10.1007/s40264-018-0779-3 (2019).

809 100 Oncology, C. B. C. f. I. *IRCC – International Registry on CIK cells*, <[https://cik-info.org/en/ircc-
810 international-registry-on-cik-cells/](https://cik-info.org/en/ircc-international-registry-on-cik-cells/)> (2009).

811 101 Wei, J. *et al.* Clinical development of CAR T cell therapy in China: 2020 update. *Cell Mol*
812 *Immunol* **18**, 792-804, doi:10.1038/s41423-020-00555-x (2021).

813 102 Mareschi, K. *et al.* Cytokine-Induced Killer (CIK) Cells, In Vitro Expanded under Good
814 Manufacturing Process (GMP) Conditions, Remain Stable over Time after Cryopreservation.
815 *Pharmaceuticals (Basel)* **13**, doi:10.3390/ph13050093 (2020).

816

817

818

819 **Table 1. Summary of included studies**

Study ID	Study type	RCT	Pt (n)	Age (range)	Male (%)	Colon primary (%)	Stage	Intervention arm/s (n)	Control arm (n)	Outcomes
Bian 2013 ³⁹	P	Yes	84	39-78	54.8	73.8	1-3	DC-CIK + ChT (42)	ChT (42)	OS, PFS, ORR, SE
Cai 2010 ⁴⁰	P	Yes	80	-	62.5	-	2-3	CIK + ChT (40)	ChT (40)	OS, PFS, SE
Cai 2013 ⁴¹	P	No	72	-	69.4	0.0	1-3	CIK + ChT (40)	ChT (32)	OS, SE
Cai 2017 ⁴²	P	No	90	30-70	70.0	-	4	DC-CIK + ChT (45)	ChT (45)	OS, PFS, SE
Chao 2016 ⁴³	R	No	66	-	68.2	-	3-4	DC-CIK +/- ChT (33)	No treatment or ChT (33)	OS, SE
Chen 2014a ⁴⁴	P	Yes	60	30-65		100.0	3-4	DC-CIK + ChT (30)	ChT (30)	OS, PFS, SE
Chen 2014b ⁴⁵	P	Yes	90	32-76	65.0	-	1-3	DC-CIK + ChT (45)	ChT (45)	OS, PFS
Chu 2016 ⁴⁶	P	Yes	89	-	51.7	-	4	CIK (30) and CIK + ChT (29)	ChT (30)	OS, PFS, SE
Deng 2018 ⁴⁷	P	Yes	60	-		-	3-4	CIK + ChT (30)	ChT (30)	OS, PFS, SE
Dong 2018 ⁴⁸	P	No	40	18-75	52.5	37.5	4	DC-CIK + ChT (20)	ChT (20)	OS, PFS, SE
Du 2013 ²⁵	P	Yes	60	-	53.3	68.3	4	CIK + ChT (30)	ChT (30)	OS, PFS, SE
Fan 2013 ⁴⁹	P	Yes	81	32-83		0.0	1-3	CIK + ChT + RT (41)	ChT + RT (40)	OS, PFS, ORR, SE
Fang 2016 ⁵⁰	P	Yes	52		59.6	-	4	CIK + ChT (26)	ChT (26)	ORR, SE
Feng 2014 ⁵¹	P	No	40	51-55	70.0	-	1-3	CIK + ChT (20)	ChT (20)	OS, PFS
Feng 2017 ⁵²	P	Yes	50	41-79	66.0	-	3	DC-CIK + ChRT (25)	ChRT (25)	PFS, ORR, SE
Gao 2014 ²⁶	P	No	26	-		-	<4	DC-CIK + ChT (13)	No treatment (13)	OS, PFS, SE
Guo 2019 ⁵³	P	Yes	68	41-83	57.4	27.9	4	DC-CIK + ChT (34)	ChT (34)	ORR
He 2018 ⁵⁴	R	-	100	40-80	60.0	-	3	DC-CIK + ChT (50)	ChT (50)	OS, ORR
Jiang 2016 ⁵⁵	P	No	98	22-78	64.3	-	3-4	DC-CIK + ChT (50)	ChT (48)	ORR
Leng 2016 ⁵⁶	R	-	90	29-66	57.8	0.0	3-4	CIK + IMRT + microwave hyperthermia (45)	IMRT + microwave hyperthermia (45)	ORR, SE
Li 2012 ⁵⁷	P	Yes	40	-	70.0	-	2-3	DC-CIK + ChT (20)	ChT (20)	OS, ORR
Li 2015 ⁵⁸	P	No	130	-	56.2	43.0	2-3	CIK + ChT + RT (65)	ChT + RT (65)	ORR, SE
Li 2016 ²⁷	U	-	60	-	63.3	63.3	4	CIK + RFA (30)	RFA (30)	ORR, SE
Li 2022 ²⁸	R	-	137	-	60.6	-	2-4	CIK + ChT (66)	ChT (71)	ORR, SE
Lin 2016 ²⁷	P	Yes	255	-	54.9	56.1	4	DC-CIK + ChT (134)	ChT (121)	OS
Liu 2014a ⁵⁹	P	Yes	56	32-72	55.4	-	4	DC-CIK + ChT (28)	ChT (28)	ORR, SE
Liu 2014b ⁶⁰	P	No	18	28-73	55.6	-	4	DC-CIK + ChT (9)	ChT (9)	ORR, SE
Liu 2016a ⁶²	P	Yes	58	35-80	63.8	-	4	DC-CIK + ChT (29)	ChT (29)	ORR
Liu 2016b ⁶³	P	Yes	80	22-82	61.3	-	1-4	DC-CIK + ChT (40)	ChT (40)	ORR
Liu 2016c ⁶⁴	R	-	90	-	64.4	0.0	1-4	DC-CIK + ChT (45)	ChT (45)	ORR

Liu 2019 ³⁰	P	Yes	70	-	68.6	40.0	2-4	DC-CIK + ChT (35)	ChT (35)	OS, ORR, SE
Liu 2020 ⁸¹	P	Yes	68	30-79	59.7	69.1	3-4	DC-CIK + ChT (34)	ChT (34)	OS
Lv 2014 ⁶⁵	P	Yes	85	-	51.8	-	3	CIK + ChT (43)	ChT (42)	ORR, SE
Ma 2019 ⁶⁶	P	Yes	50	49-77	60.0	-	2-3	DC-CIK + ChT (25)	ChT (25)	ORR, SE
Niu 2016 ⁶⁷	P	Yes	50	34-62	64.0	-	3-4	DC-CIK + ChT (25)	ChT (25)	ORR
Pan 2020a ³¹	R	-	252	-	61.5	63.5	4	CIK + ChT (126)	ChT (126)	OS, PFS
Pan 2020b ¹⁷	R	-	122	-	63.9	64.8	2-4	CIK + ChT (60)	ChT (62)	ORR
Peng 2017 ³²	P	Yes	46	-	63.0	-	2-3	CIK + ChT (23)	ChT (23)	ORR
Pu 2021 ⁶⁸	P	Yes	98	-	38.8	-	4	DC-CIK + ChT (49)	ChT (49)	SE
Rui 2012 ⁶⁹	P	Yes	90	18-60	57.8	53.3	4	DC-CIK + ChT (45)	ChT (45)	OS, ORR
Sun 2020 ⁷⁰	P	No	60	41-68	51.7	-	4	DC-CIK + ChT (30)	ChT (30)	OS, ORR, SE
Wang 2014 ⁷¹	P	No	110	-	60.0	63.6	1-3	CIK + ChT (55)	ChT (55)	OS, ORR
Wang 2016 ⁷²	P	Yes	104	32-69	58.7	-	3-4	DC-CIK + ChT (52)	ChT (52)	ORR
Wang 2017 ⁷³	P	Yes	68	-	64.1	-	3-4	DC-CIK + ChT (34)	ChT (34)	OS, ORR, SE
Wang 2019 ³³	R	-	377	-	-	-	-	CIK + ChT (97)	ChT (280)	ORR
Weng 2013 ⁷⁴	P	Yes	235	-	55.3	56.6	3-4	DC-CIK + ChT (124)	ChT (111)	ORR
Weng 2014 ⁷⁵	P	Yes	96	25-76	59.6	-	4	CIK + ChT (48)	ChT (48)	ORR
Wu 2018 ⁷⁶	R	-	132	-	66.7	51.5	4	DC-CIK + ChT + RFA (62)	ChT + RFA (70)	OS
Xie 2017 ¹⁹	R	-	142	-	55.6	-	3-4	DC-CIK + ChT +/- RT (71)	ChT +/-RT (71)	OS, ORR
Xu 2021 ³⁴	R	-	116	-	46.6	54.3	2-4	CIK + ChT (32)*	ChT (82)*	OS, ORR
Yan 2014 ⁷⁷	P	No	114	-	56.1	-	4	CIK + ChT (72)	ChT (42)	OS, PFS, ORR
Yin 2013 ⁷⁸	P	No	80	-	61.3	60.0	4	DC-CIK + ChT (40)	ChT (40)	OS, PFS, ORR
Ying 2010 ⁷⁹	R	-	102	20-86	54.9	-	1-3	DC-CIK + ChT + RT (51)	ChT + RT (51)	PFS, ORR
Yuan 2016 ⁸⁰	P	Yes	42	45-78	73.8	-	4	DC-CIK + ChT (21)	ChT (21)	OS
Yue 2016 ⁸¹	P	Yes	110	-	47.3	53.6	3-4	DC-CIK (55)	BSC (55)	OS, PFS, ORR
Zang 2019 ⁸²	P	Yes	90	-	66.7	-	3-4	DC-CIK + ChT (45)	ChT (45)	OS
Zhang 2011 ⁸³	P	Yes	63	24-82	61.9	-	3-4	DC-CIK + ChT (32)	ChT (31)	OS
Zhang 2014 ³⁵	P	Yes	60	-	63.3	56.7	1-4	CIK + ChT (30)	ChT (30)	OS, SE
Zhang 2015 ⁸⁴	R	-	84	-	54.8	-	4	DC-CIK + ChT (42)	ChT (42)	OS, PFS, ORR, SE
Zhang 2016 ²⁴	P	No	112	-	52.2	52.0	3-4	DC-CIK + ChT (65)	ChT (47)	ORR
Zhang 2017 ⁸⁵	P	Yes	118	46-78	49.2	-	4	DC-CIK + ChT (59)	ChT (59)	OS, PFS
Zhang 2022 ⁸⁶	P	No	90	43-73	67.8	51.1	3-4	DC-CIK + ChT (45)	ChT (45)	SE
Zhao 2015 ⁸⁹	P	Yes	30	32-67	70.0	-	4	DC-CIK + ChT (15)	ChT (15)	ORR
Zhao 2016 ³⁶	P	Yes	122	-	67.2	58.7	4	CIK + ChT (61)	ChT (61)	ORR, SE
Zhao 2018 ⁸⁷	P	Yes	90	40-59	63.3	-	4	CIK + ChT (45)	ChT (45)	ORR, SE

Use of cytokine-induced killer cell therapy in colorectal cancer patients: a systematic review and meta-analysis.

Zhao 2019 ⁸⁸	P	No	148	-	62.8	-	1-3	DC-CIK + ChT + RFA (73)	ChT + RFA (75)	OS
Zhou 2015 ⁹¹	P	Yes	60	45-80	68.3	78.3	4	DC-CIK + ChT (30)	ChT (30)	OS, ORR
Zhou 2016 ⁹⁰	P	No	90	-	-	-	4	DC-CIK + TACE (45)	TACE (45)	ORR, SE
Zhu 2013 ³⁷	R	-	96	-	57.3	62.1	1-4	CIK + ChT (21)	ChT (75)	OS, PFS, ORR, SE
Zhu 2014 ³⁸	R	-	351	19-92	65.2	30.8	4	DC-CIK + Standard care (100)	Standard care (251)	ORR, SE

820

821 n=number; P=prospective; R=retrospective; U=unknown; RCT= randomised controlled trial; ChT=chemotherapy; RT=radiotherapy;
 822 ChRT=concurrent chemoradiotherapy; BSC=best supportive care; IMRT=intensity modified radiotherapy; TACE=trans-arterial
 823 chemoembolization; RFA=radiofrequency ablation;*16 and 18 patients in intervention arm and 47 and 35 patients in control arm were treated in
 824 adjuvant and palliative setting, respectively.

825





Figure 1. Flow chart of study selection.

A



B




Figure 2. Comparison of CIK/DC-CIK therapy versus non-CIK/DC-CIK therapy for (A) overall survival (OS) and (B) progression-free survival (PFS). Twenty-six studies involving 3,303 patients and twenty studies involving 2,593 patients contributed data to OS and PFS analysis respectively. CIK, cytokine-induced killer cell; DC, dendritic cell.





Figure 3. CIK/DC-CIK therapy versus non-CIK/DC-CIK therapy for overall response rate (ORR). Forty-five studies involving 3,860 patients contributed data to ORR analysis. *Study Chu 2016 appears twice in the figure as it contained 3 treatment arms and data were entered separately for CIK + chemotherapy versus chemotherapy (Chu 2016 (1)) and CIK versus chemotherapy (Chu 2016 (2)) by splitting the chemotherapy group into 2 subgroups, one for each CIK + chemotherapy and CIK treatment. CIK, cytokine-induced killer cell; DC, dendritic cell.

A



B





Figure 4. Subgroup analysis by study design for (A) overall survival (OS) and (B) progression-free survival (PFS). Twenty-five studies involving 3,243 patients and nineteen studies involving 2,533 patients contributed data to OS and PFS analysis respectively.

A



B





Figure 5. Subgroup analysis by CIK therapy type (with or without DC therapy) for (A) overall survival (OS) and (B) progression-free survival (PFS). Twenty-six studies

involving 3,303 patients and twenty studies involving 2,593 patients contributed data to OS and PFS analysis respectively. CIK, cytokine-induced killer cell; DC, dendritic cell.

A



B




Figure 6. Subgroup analysis by CIK/DC-CIK therapy administration timing for (A) overall survival (OS) and (B) progression-free survival (PFS). Twenty-four studies involving 2,846 patients and seventeen studies involving 2,040 patients contributed data to OS and PFS analysis respectively. CIK, cytokine-induced killer cell; DC, dendritic cell.